Feb 22, 2024 / 01:00PM GMT
Operator
Welcome to the BioInvent Q4 Report 2023 Conference Call. (Operator Instructions) Now I will hand the conference over to the speakers: CEO Martin Welschof, CFO Stefan Ericsson. Please go ahead.
Martin Welschof - BioInvent International AB - CEO
Yes, welcome, everybody, to our year-end report. And we will guide you through a number of slides. First, I will give you a summary of what has happened with some focus areas. And then at the end, Stefan Ericsson, the CFO, will give you the financials. And I am the CEO, Martin Welschof.
So we'll start on slide number 3, where we have a summary of the main events in the fourth quarter. And I would like to start with our program, BI-1808, which is our lead program targeting TNF receptor 2. And we had very interesting, positive data from the clinical Phase 1/2a, which is currently ongoing, where we test the antibody, BI-1808, as a single agent. And we presented that at SITC. And I will come back to the data a little bit later. Then we also have shown preclinical data providing clear evidence of the potential of our
Q4 2023 BioInvent International AB Earnings Call Transcript
Feb 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers